SleepWell Trade

Trend-Following Backtester · Guide · backtest 한국어

equity · US

Humacyte, Inc. backtest

10 trend-following strategies were compared on the full daily history of Humacyte, Inc.. 10 beat buy-and-hold CAGR; MACD ranks first by Sharpe, matching the main backtester. The return/drawdown alternative is ADX / DI 방향성 (CAGR 0.9%, MDD -4.3%).

Data 2020-12-01 ~ 2026-07-31daily bars 1,422 (5.7 years)Costs 0.5%Venue XNASMonthly snapshot 2026-07-31

Results by strategy

10 of 10 beat buy and hold (CAGR -37.9%, drawdown -96.6%).

Sharpe leader (same as main): MACD — CAGR 16.7%, MDD -78.1%, Sharpe 0.57, 50% exposure.

Return/drawdown alternative: ADX / DI 방향성 — CAGR is 54.6%p higher than buy and hold, while drawdown improves by 18.6%p (CAGR 0.9%, MDD -4.3%, exposure 1%).

The alternative must retain 75% of buy-and-hold CAGR, improve drawdown by at least 20% and 5 percentage points, and stay below 95% exposure; the ranking weights return retention 60% and drawdown improvement 40%.

Strategy · parametersCAGRMDDSharpeCalmarTotalTradesExposure
MACD
fast=9, slow=22, signal=15
16.7%-78.1%0.570.212.4x8350%
Supertrend
period=11, mult=2.8
4.0%-78.1%0.380.051.2x3638%
ADX / DI 방향성
period=39, threshold=33
0.9%-4.3%0.350.221.1x21%
EMA 크로스오버
fast=48, slow=228
1.8%-54.8%0.240.031.1x416%
ROC 모멘텀
n=135, threshold=0.1
-1.6%-64.7%0.19-0.030.9x3620%
볼린저 밴드 돌파
n=19, k=2
-4.3%-66.2%0.19-0.060.8x5425%
Parabolic SAR
step=0.035, maxStep=0.28
-11.8%-85.6%0.13-0.140.5x15144%
SMA 크로스오버
fast=47, slow=153
-4.2%-64.7%0.13-0.070.8x824%
Keltner 채널 돌파
emaPeriod=28, atrPeriod=10, mult=1.4
-9.0%-68.4%0.09-0.130.6x4224%
Donchian 채널 돌파
entryN=21, exitN=76
-22.9%-85.5%0.02-0.270.2x1762%
Buy and hold-37.9%-96.6%-0.05-0.390.1x1100%
0.1 1x 2021 2022 2023 2024 2025 2026 MACDBuy and hold
MACD: Solid strategy line versus dashed buy-and-hold line. Log scale.
0% -24% -48% -72% -97% 2021 2022 2023 2024 2025 2026 Buy and holdMACD
MACD maximum drawdown -78.1% (2024-07-31 → 2025-05-09), prior peak not yet recovered.

Rules of the top strategy

Looks at the gap (MACD) between a short and long average crossing its own signal line.

Method and caveats

Past performance does not guarantee future returns. Parameters were selected on the same full-history sample using sharpe over 40 trials per strategy, so results contain in-sample bias. 0.5% trading costs are included; taxes, slippage and rejected orders are not.
Re-run the same setupMore US assetsAll asset reports

Read next